Vaginal Laser To Improve Symptomatic Vulvovaginal Atrophy And Sexual Function In Breast Cancer Patients: Report From Laava Pilot Study.

10064 Background: Vulvovaginal atrophy (VVA) is a commonly reported issue among breast cancer patients (pts), and its etiology is multifactorial. The use of systemic and topical estrogens to treat VVA has traditionally been discouraged in hormone positive breast cancer. Laser therapy has been reported to improve symptoms from VVA in women with menopause. We aimed to assess the symptomatic benefit and the impact on sexual function of this treatment in women with early breast cancer (EBC). Methods: We performed a single arm investigator initiated pilot study of female EBC pts with symptomatic VVA. 29 pts were recruited between February 2016 and August 2017. 3 pts were not enrolled; 2 had medical conditions that excluded them from treatment, 1 withdrew consent prior to commencing. Baseline demographic data was collected on all pts. A total of 3 vaginal fractional CO2 laser treatments were administered approximately 4 weeks apart for each pt. Questionnaires were completed at baseline, prior to each subsequent treatment and 4 weeks after completion of treatment. Our primary endpoint was symptomatic improvement of VVA (dryness, itch, burning, dysuria and dyspareunia) at 12 weeks on a 10cm visual analog scale (VAS). Our secondary endpoint was improvement in sexual function using the Female Sexual Function Index (FSFI) at 12 weeks. Statistical analysis was performed with a Wilcoxon Signed Rank test. Results: 26 pts were enrolled in our study with a median age of 55. All pts were post-menopausal. 25 pts had received anti-estrogen therapy as a part of their breast cancer treatment. All pts received the 3 pre-planned laser treatments, and questionnaire compliance was high (98%). There was significant improvement in VVA symptoms after treatment on a 10cm VAS (table 1) and in sexual function demonstrated on the FSFI (p = < 0.001). Conclusions: EBC pts had improvement in all 5 domains of VVA symptoms, as well as improvement in sexual function. Further randomized sham-controlled trials are needed to further assess this treatment. Change in VVA symptoms on 10cm VAS score. Variable Mean absolute change P value Dryness 4.33 < 0.001 Itch 3.67 < 0.001 Burning 2.93 0.003 Dysuria 3.53 < 0.001 Dyspareunia 3.84 < 0.001